Invited Review ArticlesUse of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy?Zhao, Daniel BA*; Zhang, Sandy BA*; Igawa, Teryn BA*; Frishman, William MD†Author Information From the *New York Medical College/Westchester Medical Center, Valhalla, NY †Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY. Disclosure: The authors declare no conflict of interest. Both S.Z. and T.I. are second authors as they worked on this manuscript equally. Correspondence: William H. Frishman, MD, Department of Medicine, New York Medical College, 40 Sunshine Cottage Road, Valhalla, NY 10595. E-mail:[email protected]; [email protected]. Cardiology in Review: November/December 2020 - Volume 28 - Issue 6 - p 303-307 doi: 10.1097/CRD.0000000000000340 Buy Metrics Abstract Severe acute respiratory distress syndrome coronavirus 2 (COVID-19) is the cause of the current pandemic, which remains a tremendous cause of morbidity and mortality worldwide. Although there are numerous trials underway, there is currently no medication known to cure the infection. Nonsteroidal anti-inflammatory drugs (NSAIDs) are inexpensive, widely available medications with antiviral and anti-inflammatory properties and may have utility as an adjunct therapy to improve outcomes in patients with severe COVID-19 infection. A thorough PubMed literature review on the therapeutic use of NSAID was conducted to provide a comprehensive perspective of the role of NSAIDs in treating COVID-19. NSAIDs may be a useful adjunct therapy for patients with severe COVID-19 infection, but further investigation and clinical trials are necessary to ensure their safety and efficacy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.